Combination of sacubitril valsartan and vericiguat in patients with heart failure and reduced ejection fraction

Combination of sacubitril valsartan and vericiguat in patients with heart failure and reduced ejection fraction - Combination of sacubitril valsartan and vericiguat in patients with heart failure : SALVAGE trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046455

Enrollment

Registered

2021-12-23

Start date

2021-12-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

Randomly assigned to sacubitril / valsartan alone group and the sacubitril / valsartan + vericiguat combination group Randomly assigned to sacubitril / valsartan alone group and the sacubitril / valsa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Heart failure with reduced ejection fraction

Exclusion criteria

Exclusion criteria: Chronic renal disease (crea>2.0)

Design outcomes

Primary

Measure	Time frame
NT-proBNP at 6 month and i year later	—

Countries

Japan

Contacts

Public ContactTakatoshi Wakeyama

Japan Community Healthcare Organization Tokuyama Central Hospital Division of Cardiology

wakeyama@icloud.com0834-28-4411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026